yahoo_financeOriginal article
OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain
Phase 3urcosimodPositive
AI Analysis
Summary
OKYO Pharma reported receiving FDA feedback and announced the advancement of urcosimod into Phase 3 clinical trials for the treatment of neuropathic corneal pain.
Clinical Trial Data
Phase
Phase 3
Outcome Details
FDA feedback received; Phase 3 trial advancement
Importance:6/10
Sentiment:
0.60
FDA feedbackPhase 3 advancementneuropathic corneal painophthalmology
Related Companies
Read the original article
Published by yahoo_finance on July 8, 2026 12:33 PM